In contrast, CYP1A2 activity was found to decrease linearly with decreasing liver functions and metabolism of mephenytoin by CYP2C19 was already severely impaired by 63% in patients with mild liver disease (Pugh score 5 or 6) [163]. The gene discussed is CYP1A2; the disease is liver disorder.